Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Abstract Background A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected...

Full description

Bibliographic Details
Main Authors: Erlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, Cecilie J. Sandberg, Swapnil Potdar, Aija Kyttälä, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Glioblastoma
Glioblastoma stem cells
High-throughput drug screening
Individualized medicine
Drug sensitivity
Functional precision medicine
Online Access:http://link.springer.com/article/10.1186/s12885-019-5861-4

Internet

http://link.springer.com/article/10.1186/s12885-019-5861-4

Similar Items